ADAM17 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, targeting the PD1/PDL1 axis via PD-1 KO and ADAM17 KO has been shown to increase antitumor activity (i) in a xenograft model of ovarian cancer and (ii) against chronic myeloid leukemia (CML) and AML cell lines in vitro (117).